Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin: a Dutch population-based study

C. Bakkers*, R. van Der Meer, R. M. Roumen, R. J. Lurvink, V. E. Lemmens, F. N. van Erning, I. H. de Hingh

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Objective The aim of this nationwide study was to provide insight in the incidence, risk factors, treatment, and survival of patients with ovarian metastases from colorectal cancer (CRC). Methods Data from the Netherlands Cancer Registry were used. All newly diagnosed female CRC patients between 2008 and 2016 were included. Treatment was categorized as follows: cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (CRS-HIPEC); resection of the primary tumor; palliative treatment; and no treatment. Overall survival (OS) was investigated using Kaplan-Meier and multivariable Cox regression analyses. Results Of 53,883 female CRC patients, 11,343 (21.1%) had metastases at time of diagnosis. Among them, 471 (4.2%) had ovarian metastases. Within latter group, 27.2% received CRS-HIPEC; 38.4% underwent resection of the primary tumor; 25.3% received palliative treatment; and 9.1% received no treatment. Median OS of all patients with ovarian metastases was 17.5 months. In patients receiving CRS-HIPEC, OS was significantly longer than in patients undergoing resection only (median OS 34.1 vs. 17.5 months, adjusted HR 0.44 [0.33-0.66]). Five-year OS was 28.5% for patients having underwent CRS-HIPEC, 11.0% for patients having underwent resection of the primary tumor, 1.2% for patients having underwent palliative treatment, and 0.0% for patients without treatment. Conclusions Synchronous ovarian metastases are diagnosed in 4.2% of female colorectal patients presenting with metastatic disease. Risk factors are young age, T4/N+ tumor and histology of signet ring cell carcinoma. Median OS of the entire cohort was 17.5 months, ranging from 3.1 months in patients without treatment to 34.1 months in patients undergoing CRS-HIPEC.

Original languageEnglish
Pages (from-to)1035-1044
Number of pages10
JournalInternational Journal of Colorectal Disease
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Ovarian metastases
  • Colorectal cancer
  • Survival
  • PERIOPERATIVE INTRAPERITONEAL CHEMOTHERAPY
  • PROPHYLACTIC OOPHORECTOMY
  • CYTOREDUCTIVE SURGERY
  • KRUKENBERG TUMORS
  • CANCER
  • COLON
  • CARCINOMATOSIS
  • WOMEN

Cite this